Taking advantage of the fact that IL-1 antagonism is approved in several countries for the treatment of gout and rheumatoid arthritis, clinicians may already use this anti-inflammatory strategy in the presence of concomitant type 2 diabetes. The gene discussed is IL1A; the disease is type 2 diabetes mellitus.